Floxacillin

Floxacillin

SCHEMBL855083

Cc1onc(-c2c(F)cccc2Cl)c1C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)O.[NaH]

nearest known ligand 0.98

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Floxacillin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ABCB11 O95342 3/20 0.98
CYP1A2 P05177 1/20 0.98
LMNA P02545 3/20 0.82
HPGD P15428 4/20 0.75
MEN1 O00255 2/20 0.75
KMT2A Q03164 2/20 0.75
TDP1 Q9NUW8 1/20 0.75
SLCO1B3 Q9NPD5 1/20 0.74
SLCO1B1 Q9Y6L6 1/20 0.74
ALDH1A1 P00352 2/20 0.62
SMN1; SMN2 Q16637 2/20 0.62
PTGS1 P23219 1/20 0.55
PDE3A Q14432 1/20 0.55
MAPT P10636 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Floxacillin SCHEMBL2636814 0.99 ABCB11 (0.97) ABCB11CYP1A2LMNAHPGDMEN1
Floxacillin SCHEMBL3823 0.99 ABCB11 (1.00) ABCB11CYP1A2LMNAHPGDMEN1
Floxacillin SCHEMBL22651560 0.99 ABCB11 (1.00) ABCB11CYP1A2LMNAHPGDMEN1
Floxacillin SCHEMBL14126462 0.99 ABCB11 (1.00) ABCB11CYP1A2LMNAHPGDMEN1
Floxacillin SCHEMBL1458003 0.99 ABCB11 (1.00) ABCB11CYP1A2LMNAHPGDMEN1
Dicloxacillin SCHEMBL21643600 0.98 ABCB11 (0.98) ABCB11CYP1A2LMNAHPGDMEN1
Floxacillin SCHEMBL1442294 0.98 ABCB11 (0.98) ABCB11CYP1A2LMNAHPGDMEN1
Floxacillin SCHEMBL28086634 0.95 ABCB11 (0.92) ABCB11CYP1A2LMNAHPGDMEN1
Dicloxacillin SCHEMBL41517 0.95 ABCB11 (0.98) ABCB11CYP1A2LMNAHPGDMEN1
Dicloxacillin SCHEMBL28536434 0.95 ABCB11 (0.98) ABCB11CYP1A2LMNAHPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 736 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4566590-A1 TASTE-MASKING MICROSPHERE, PREPARATION PROCESS THEREFOR, AND USE THEREOF Harbin Kanon Pharmaceutical Co., Ltd (CN) 2025-06-11 EP claimed
US-12274830-B2 Nitric oxide inhalation therapy for infants with bronchiolitis BEYOND AIR LTD (IL) 2025-04-15 US claimed
CN-221933766-U Uniform mixing device for amoxicillin sodium and flucloxacillin sodium 山西振东泰盛制药有限公司 2024-11-01 CN claimed
CN-117503707-B Taste-masking microsphere and preparation process and application thereof 哈尔滨市康隆药业有限责任公司 2024-08-23 CN claimed
US-20240173512-A1 METHODS FOR POTENTIATING ANTIMICROBIAL AGENTS STREETERVILLE CAPITAL, LLC 2024-05-30 US claimed
WO-2024027794-A1 TASTE-MASKING MICROSPHERE, PREPARATION PROCESS THEREFOR, AND USE THEREOF 哈尔滨市康隆药业有限责任公司 2024-02-08 WO claimed
US-11890421-B2 Methods for potentiating antimicrobial agents BEYOND AIR LTD (IL) 2024-02-06 US claimed
CN-117503707-A Taste-masking microsphere and preparation process and application thereof 哈尔滨市康隆药业有限责任公司 2024-02-06 CN claimed
US-20230346879-A1 COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2023-11-02 US claimed
CN-114163360-B Synthesis and taste masking application of water-soluble biphenyl aromatic hydrocarbon 天津师范大学 2023-03-24 CN claimed
US-6500459-B1 PHARMACEUTICAL COMPOSITION FOR CONTROLLED ONSET AND SUSTAINED RELEASE OF ACTIVE INGREDIENT COMPRISING CORE COMPRISING ACTIVE INGREDIENT, HYDROPHILIC CARRIER AND HYDRODYNAMIC DIFFUSION ENHANCER WITH FUNCTIONAL COATING MEMBRANE SURROUNDING CORE CHHABRA HARINDERPAL (US) 2002-12-31 US claimed
WO-2002098464-A2 LIQUID POLYMER COMPOSITION FOR PREVENTION AND TREATMENT OF THE ORAL CAVITY DISEASES ITALMED S.N.C. DI GALLI G. & PACINI G. (IT) 2002-12-12 WO claimed
EP-1262172-A1 Liquid polymer composition for prevention and treatment of the oral cavity diseases Italmed S.N.C. Di Galli G. & Pacini G. (IT) 2002-12-04 EP claimed
US-5811547-A Method for inducing crystalline state transition in medicinal substance NIPPON SHINYAJU CO., LTD. (JP) 1998-09-22 US claimed
US-4952402-A EDIBLE TASTE-MASKED DRUGS; MICROMATRIX ACTIVE MATERIAL COATED WITH NONTOXIC POLYMER; LIQUIDS; TABLETS ELAN CORPORATION, P.L.C. (IE) 1990-08-28 US claimed
US-4369172-A Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose FOREST LABORATORIES INC. (US) 1983-01-18 US claimed
EP-0010904-B1 INTRAMAMMARY COMPOSITIONS AND PROCESS FOR THEIR PREPARATION BEECHAM GROUP PLC (GB) 1982-05-05 EP claimed
US-4282202-A Intramammary compositions BEECHAM GROUP LIMITED (GB) 1981-08-04 US claimed
EP-0010904-A2 Intramammary compositions and process for their preparation BEECHAM GROUP PLC (GB) 1980-05-14 EP claimed
EP-0008178-A2 Powder, process for its preparation, container holding it, and syrup comprising the powder reconstituted with water BEECHAM GROUP PLC (GB) 1980-02-20 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230346879-A1 COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS RAB5IF, CLTB, TBK1 ABCB11 2506/4885CYP1A2 4441/4885LMNA 3886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.